High-Throughput Assessment of Real-World Medication Effects on QT Interval Prolongation: Observational Study
Drug-induced prolongation of the corrected QT interval (QTc) increases the risk for Torsades de Pointes (TdP) and sudden cardiac death. Medication effects on the QTc have been studied in controlled settings but may not be well evaluated in real-world settings where medication effects may be modulate...
Saved in:
Published in | JMIR cardio Vol. 7; p. e41055 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Canada
JMIR Publications
20.01.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Drug-induced prolongation of the corrected QT interval (QTc) increases the risk for Torsades de Pointes (TdP) and sudden cardiac death. Medication effects on the QTc have been studied in controlled settings but may not be well evaluated in real-world settings where medication effects may be modulated by patient demographics and comorbidities as well as the usage of other concomitant medications.
We demonstrate a new, high-throughput method leveraging electronic health records (EHRs) and the Surescripts pharmacy database to monitor real-world QTc-prolonging medication and potential interacting effects from demographics and comorbidities.
We included all outpatient electrocardiograms (ECGs) from September 2008 to December 2019 at a large academic medical system, which were in sinus rhythm with a heart rate of 40-100 beats per minute, QRS duration of <120 milliseconds, and QTc of 300-700 milliseconds, determined using the Bazett formula. We used prescription information from the Surescripts pharmacy database and EHR medication lists to classify whether a patient was on a medication during an ECG. Negative control ECGs were obtained from patients not currently on the medication but who had been or would be on that medication within 1 year. We calculated the difference in mean QTc between ECGs of patients who are on and those who are off a medication and made comparisons to known medication TdP risks per the CredibleMeds.org database. Using linear regression analysis, we studied the interaction of patient-level demographics or comorbidities on medication-related QTc prolongation.
We analyzed the effects of 272 medications on 310,335 ECGs from 159,397 individuals. Medications associated with the greatest QTc prolongation were dofetilide (mean QTc difference 21.52, 95% CI 10.58-32.70 milliseconds), mexiletine (mean QTc difference 18.56, 95% CI 7.70-29.27 milliseconds), amiodarone (mean QTc difference 14.96, 95% CI 13.52-16.33 milliseconds), rifaximin (mean QTc difference 14.50, 95% CI 12.12-17.13 milliseconds), and sotalol (mean QTc difference 10.73, 95% CI 7.09-14.37 milliseconds). Several top QT prolonging medications such as rifaximin, lactulose, cinacalcet, and lenalidomide were not previously known but have plausible mechanistic explanations. Significant interactions were observed between demographics or comorbidities and QTc prolongation with many medications, such as coronary disease and amiodarone.
We demonstrate a new, high-throughput technique for monitoring real-world effects of QTc-prolonging medications from readily accessible clinical data. Using this approach, we confirmed known medications for QTc prolongation and identified potential new associations and demographic or comorbidity interactions that could supplement findings in curated databases. Our single-center results would benefit from additional verification in future multisite studies that incorporate larger numbers of patients and ECGs along with more precise medication adherence and comorbidity data. |
---|---|
AbstractList | Drug-induced prolongation of the corrected QT interval (QTc) increases the risk for Torsades de Pointes (TdP) and sudden cardiac death. Medication effects on the QTc have been studied in controlled settings but may not be well evaluated in real-world settings where medication effects may be modulated by patient demographics and comorbidities as well as the usage of other concomitant medications.
We demonstrate a new, high-throughput method leveraging electronic health records (EHRs) and the Surescripts pharmacy database to monitor real-world QTc-prolonging medication and potential interacting effects from demographics and comorbidities.
We included all outpatient electrocardiograms (ECGs) from September 2008 to December 2019 at a large academic medical system, which were in sinus rhythm with a heart rate of 40-100 beats per minute, QRS duration of <120 milliseconds, and QTc of 300-700 milliseconds, determined using the Bazett formula. We used prescription information from the Surescripts pharmacy database and EHR medication lists to classify whether a patient was on a medication during an ECG. Negative control ECGs were obtained from patients not currently on the medication but who had been or would be on that medication within 1 year. We calculated the difference in mean QTc between ECGs of patients who are on and those who are off a medication and made comparisons to known medication TdP risks per the CredibleMeds.org database. Using linear regression analysis, we studied the interaction of patient-level demographics or comorbidities on medication-related QTc prolongation.
We analyzed the effects of 272 medications on 310,335 ECGs from 159,397 individuals. Medications associated with the greatest QTc prolongation were dofetilide (mean QTc difference 21.52, 95% CI 10.58-32.70 milliseconds), mexiletine (mean QTc difference 18.56, 95% CI 7.70-29.27 milliseconds), amiodarone (mean QTc difference 14.96, 95% CI 13.52-16.33 milliseconds), rifaximin (mean QTc difference 14.50, 95% CI 12.12-17.13 milliseconds), and sotalol (mean QTc difference 10.73, 95% CI 7.09-14.37 milliseconds). Several top QT prolonging medications such as rifaximin, lactulose, cinacalcet, and lenalidomide were not previously known but have plausible mechanistic explanations. Significant interactions were observed between demographics or comorbidities and QTc prolongation with many medications, such as coronary disease and amiodarone.
We demonstrate a new, high-throughput technique for monitoring real-world effects of QTc-prolonging medications from readily accessible clinical data. Using this approach, we confirmed known medications for QTc prolongation and identified potential new associations and demographic or comorbidity interactions that could supplement findings in curated databases. Our single-center results would benefit from additional verification in future multisite studies that incorporate larger numbers of patients and ECGs along with more precise medication adherence and comorbidity data. BackgroundDrug-induced prolongation of the corrected QT interval (QTc) increases the risk for Torsades de Pointes (TdP) and sudden cardiac death. Medication effects on the QTc have been studied in controlled settings but may not be well evaluated in real-world settings where medication effects may be modulated by patient demographics and comorbidities as well as the usage of other concomitant medications. ObjectiveWe demonstrate a new, high-throughput method leveraging electronic health records (EHRs) and the Surescripts pharmacy database to monitor real-world QTc-prolonging medication and potential interacting effects from demographics and comorbidities. MethodsWe included all outpatient electrocardiograms (ECGs) from September 2008 to December 2019 at a large academic medical system, which were in sinus rhythm with a heart rate of 40-100 beats per minute, QRS duration of <120 milliseconds, and QTc of 300-700 milliseconds, determined using the Bazett formula. We used prescription information from the Surescripts pharmacy database and EHR medication lists to classify whether a patient was on a medication during an ECG. Negative control ECGs were obtained from patients not currently on the medication but who had been or would be on that medication within 1 year. We calculated the difference in mean QTc between ECGs of patients who are on and those who are off a medication and made comparisons to known medication TdP risks per the CredibleMeds.org database. Using linear regression analysis, we studied the interaction of patient-level demographics or comorbidities on medication-related QTc prolongation. ResultsWe analyzed the effects of 272 medications on 310,335 ECGs from 159,397 individuals. Medications associated with the greatest QTc prolongation were dofetilide (mean QTc difference 21.52, 95% CI 10.58-32.70 milliseconds), mexiletine (mean QTc difference 18.56, 95% CI 7.70-29.27 milliseconds), amiodarone (mean QTc difference 14.96, 95% CI 13.52-16.33 milliseconds), rifaximin (mean QTc difference 14.50, 95% CI 12.12-17.13 milliseconds), and sotalol (mean QTc difference 10.73, 95% CI 7.09-14.37 milliseconds). Several top QT prolonging medications such as rifaximin, lactulose, cinacalcet, and lenalidomide were not previously known but have plausible mechanistic explanations. Significant interactions were observed between demographics or comorbidities and QTc prolongation with many medications, such as coronary disease and amiodarone. ConclusionsWe demonstrate a new, high-throughput technique for monitoring real-world effects of QTc-prolonging medications from readily accessible clinical data. Using this approach, we confirmed known medications for QTc prolongation and identified potential new associations and demographic or comorbidity interactions that could supplement findings in curated databases. Our single-center results would benefit from additional verification in future multisite studies that incorporate larger numbers of patients and ECGs along with more precise medication adherence and comorbidity data. Drug-induced prolongation of the corrected QT interval (QTc) increases the risk for Torsades de Pointes (TdP) and sudden cardiac death. Medication effects on the QTc have been studied in controlled settings but may not be well evaluated in real-world settings where medication effects may be modulated by patient demographics and comorbidities as well as the usage of other concomitant medications.BACKGROUNDDrug-induced prolongation of the corrected QT interval (QTc) increases the risk for Torsades de Pointes (TdP) and sudden cardiac death. Medication effects on the QTc have been studied in controlled settings but may not be well evaluated in real-world settings where medication effects may be modulated by patient demographics and comorbidities as well as the usage of other concomitant medications.We demonstrate a new, high-throughput method leveraging electronic health records (EHRs) and the Surescripts pharmacy database to monitor real-world QTc-prolonging medication and potential interacting effects from demographics and comorbidities.OBJECTIVEWe demonstrate a new, high-throughput method leveraging electronic health records (EHRs) and the Surescripts pharmacy database to monitor real-world QTc-prolonging medication and potential interacting effects from demographics and comorbidities.We included all outpatient electrocardiograms (ECGs) from September 2008 to December 2019 at a large academic medical system, which were in sinus rhythm with a heart rate of 40-100 beats per minute, QRS duration of <120 milliseconds, and QTc of 300-700 milliseconds, determined using the Bazett formula. We used prescription information from the Surescripts pharmacy database and EHR medication lists to classify whether a patient was on a medication during an ECG. Negative control ECGs were obtained from patients not currently on the medication but who had been or would be on that medication within 1 year. We calculated the difference in mean QTc between ECGs of patients who are on and those who are off a medication and made comparisons to known medication TdP risks per the CredibleMeds.org database. Using linear regression analysis, we studied the interaction of patient-level demographics or comorbidities on medication-related QTc prolongation.METHODSWe included all outpatient electrocardiograms (ECGs) from September 2008 to December 2019 at a large academic medical system, which were in sinus rhythm with a heart rate of 40-100 beats per minute, QRS duration of <120 milliseconds, and QTc of 300-700 milliseconds, determined using the Bazett formula. We used prescription information from the Surescripts pharmacy database and EHR medication lists to classify whether a patient was on a medication during an ECG. Negative control ECGs were obtained from patients not currently on the medication but who had been or would be on that medication within 1 year. We calculated the difference in mean QTc between ECGs of patients who are on and those who are off a medication and made comparisons to known medication TdP risks per the CredibleMeds.org database. Using linear regression analysis, we studied the interaction of patient-level demographics or comorbidities on medication-related QTc prolongation.We analyzed the effects of 272 medications on 310,335 ECGs from 159,397 individuals. Medications associated with the greatest QTc prolongation were dofetilide (mean QTc difference 21.52, 95% CI 10.58-32.70 milliseconds), mexiletine (mean QTc difference 18.56, 95% CI 7.70-29.27 milliseconds), amiodarone (mean QTc difference 14.96, 95% CI 13.52-16.33 milliseconds), rifaximin (mean QTc difference 14.50, 95% CI 12.12-17.13 milliseconds), and sotalol (mean QTc difference 10.73, 95% CI 7.09-14.37 milliseconds). Several top QT prolonging medications such as rifaximin, lactulose, cinacalcet, and lenalidomide were not previously known but have plausible mechanistic explanations. Significant interactions were observed between demographics or comorbidities and QTc prolongation with many medications, such as coronary disease and amiodarone.RESULTSWe analyzed the effects of 272 medications on 310,335 ECGs from 159,397 individuals. Medications associated with the greatest QTc prolongation were dofetilide (mean QTc difference 21.52, 95% CI 10.58-32.70 milliseconds), mexiletine (mean QTc difference 18.56, 95% CI 7.70-29.27 milliseconds), amiodarone (mean QTc difference 14.96, 95% CI 13.52-16.33 milliseconds), rifaximin (mean QTc difference 14.50, 95% CI 12.12-17.13 milliseconds), and sotalol (mean QTc difference 10.73, 95% CI 7.09-14.37 milliseconds). Several top QT prolonging medications such as rifaximin, lactulose, cinacalcet, and lenalidomide were not previously known but have plausible mechanistic explanations. Significant interactions were observed between demographics or comorbidities and QTc prolongation with many medications, such as coronary disease and amiodarone.We demonstrate a new, high-throughput technique for monitoring real-world effects of QTc-prolonging medications from readily accessible clinical data. Using this approach, we confirmed known medications for QTc prolongation and identified potential new associations and demographic or comorbidity interactions that could supplement findings in curated databases. Our single-center results would benefit from additional verification in future multisite studies that incorporate larger numbers of patients and ECGs along with more precise medication adherence and comorbidity data.CONCLUSIONSWe demonstrate a new, high-throughput technique for monitoring real-world effects of QTc-prolonging medications from readily accessible clinical data. Using this approach, we confirmed known medications for QTc prolongation and identified potential new associations and demographic or comorbidity interactions that could supplement findings in curated databases. Our single-center results would benefit from additional verification in future multisite studies that incorporate larger numbers of patients and ECGs along with more precise medication adherence and comorbidity data. Background:Drug-induced prolongation of the corrected QT interval (QTc) increases the risk for Torsades de Pointes (TdP) and sudden cardiac death. Medication effects on the QTc have been studied in controlled settings but may not be well evaluated in real-world settings where medication effects may be modulated by patient demographics and comorbidities as well as the usage of other concomitant medications.Objective:We demonstrate a new, high-throughput method leveraging electronic health records (EHRs) and the Surescripts pharmacy database to monitor real-world QTc-prolonging medication and potential interacting effects from demographics and comorbidities.Methods:We included all outpatient electrocardiograms (ECGs) from September 2008 to December 2019 at a large academic medical system, which were in sinus rhythm with a heart rate of 40-100 beats per minute, QRS duration of <120 milliseconds, and QTc of 300-700 milliseconds, determined using the Bazett formula. We used prescription information from the Surescripts pharmacy database and EHR medication lists to classify whether a patient was on a medication during an ECG. Negative control ECGs were obtained from patients not currently on the medication but who had been or would be on that medication within 1 year. We calculated the difference in mean QTc between ECGs of patients who are on and those who are off a medication and made comparisons to known medication TdP risks per the CredibleMeds.org database. Using linear regression analysis, we studied the interaction of patient-level demographics or comorbidities on medication-related QTc prolongation.Results:We analyzed the effects of 272 medications on 310,335 ECGs from 159,397 individuals. Medications associated with the greatest QTc prolongation were dofetilide (mean QTc difference 21.52, 95% CI 10.58-32.70 milliseconds), mexiletine (mean QTc difference 18.56, 95% CI 7.70-29.27 milliseconds), amiodarone (mean QTc difference 14.96, 95% CI 13.52-16.33 milliseconds), rifaximin (mean QTc difference 14.50, 95% CI 12.12-17.13 milliseconds), and sotalol (mean QTc difference 10.73, 95% CI 7.09-14.37 milliseconds). Several top QT prolonging medications such as rifaximin, lactulose, cinacalcet, and lenalidomide were not previously known but have plausible mechanistic explanations. Significant interactions were observed between demographics or comorbidities and QTc prolongation with many medications, such as coronary disease and amiodarone.Conclusions:We demonstrate a new, high-throughput technique for monitoring real-world effects of QTc-prolonging medications from readily accessible clinical data. Using this approach, we confirmed known medications for QTc prolongation and identified potential new associations and demographic or comorbidity interactions that could supplement findings in curated databases. Our single-center results would benefit from additional verification in future multisite studies that incorporate larger numbers of patients and ECGs along with more precise medication adherence and comorbidity data. |
Author | Yuan, Neal Chugh, Sumeet Botting, Patrick Ebinger, Joseph Oesterle, Adam Albert, Christine Ouyang, David |
AuthorAffiliation | 1 Division of Cardiology, Department of Medicine San Francisco Veteran Affairs Medical Center San Francisco, CA United States 2 Smidt Heart Institute, Department of Cardiology Cedars-Sinai Medical Center Los Angeles, CA United States |
AuthorAffiliation_xml | – name: 2 Smidt Heart Institute, Department of Cardiology Cedars-Sinai Medical Center Los Angeles, CA United States – name: 1 Division of Cardiology, Department of Medicine San Francisco Veteran Affairs Medical Center San Francisco, CA United States |
Author_xml | – sequence: 1 givenname: Neal orcidid: 0000-0001-5782-7437 surname: Yuan fullname: Yuan, Neal organization: Division of Cardiology, Department of Medicine, San Francisco Veteran Affairs Medical Center, San Francisco, CA, United States – sequence: 2 givenname: Adam orcidid: 0000-0003-1847-8662 surname: Oesterle fullname: Oesterle, Adam organization: Division of Cardiology, Department of Medicine, San Francisco Veteran Affairs Medical Center, San Francisco, CA, United States – sequence: 3 givenname: Patrick orcidid: 0000-0003-0967-5728 surname: Botting fullname: Botting, Patrick organization: Smidt Heart Institute, Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, United States – sequence: 4 givenname: Sumeet orcidid: 0000-0002-4417-5326 surname: Chugh fullname: Chugh, Sumeet organization: Smidt Heart Institute, Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, United States – sequence: 5 givenname: Christine orcidid: 0000-0002-2081-1121 surname: Albert fullname: Albert, Christine organization: Smidt Heart Institute, Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, United States – sequence: 6 givenname: Joseph orcidid: 0000-0002-0587-1572 surname: Ebinger fullname: Ebinger, Joseph organization: Smidt Heart Institute, Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, United States – sequence: 7 givenname: David orcidid: 0000-0002-3813-7518 surname: Ouyang fullname: Ouyang, David organization: Smidt Heart Institute, Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, United States |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36662566$$D View this record in MEDLINE/PubMed |
BookMark | eNpdkttq3DAQQEVJaC7dXyiGUuiLG10sWepDIYRcFlLSy5Y-Clkeeb1ora1kB_L30e6mIemTRjOHwzAzJ-hgCAMgNCP4MyVKnFUEc_4GHVMuSEkwIQcv4iM0S2mFMaacEF7xt-iICSFyXRwjf9N3y3KxjGHqlptpLM5TgpTWMIxFcMVPML78E6Jvi2_Q9taMfRiKS-fAjqnI4Y9FMR9GiPfGF99j8GHodsyX4q5J2_T2k2u_xql9eIcOnfEJZk_vKfp9dbm4uClv767nF-e3pWU15aVowHBLqZIGpOIKG2ybxrFG8oZYWWFGHCjOaqVsVWHBpWoxSNpQJ7GoODtF8723DWalN7Ffm_igg-n1LhFip00ce-tBCwdAFOZWMlpB66S1BCuiJMFZKOrs-rp3baZmDa3Ng4nGv5K-rgz9UnfhXiuppGQiCz49CWL4O0Ea9bpPFrw3A4QpaVoLSRmnXGX0w3_oKkwxjy9TitSCkEptO_q4p2wMKUVwz80QrLfnoHfnkLn3Lzt_pv4tnz0CzY2vww |
CitedBy_id | crossref_primary_10_1186_s40780_023_00322_w crossref_primary_10_1681_ASN_0000000000000291 crossref_primary_10_1093_ndt_gfad210 |
Cites_doi | 10.1161/CIRCOUTCOMES.113.000152 10.1001/jama.2015.10725 10.5152/AnatolJCardiol.2015.6284 10.3265/Nefrologia.pre2012.Oct.11679 10.1016/j.mayocp.2013.01.013 10.1161/CIRCEP.118.007280 10.11909/j.issn.1671-5411.2016.09.013 10.1001/jamaoncol.2019.1870 10.1016/j.jacep.2016.12.005 10.1016/j.jacc.2010.01.001 10.1161/jaha.116.003264 10.1001/jama.270.21.2590 10.1016/j.rmed.2016.12.003 10.1016/j.hrthm.2015.07.011 10.1016/S0140-6736(99)02107-8 10.1111/bcpt.12081 10.1016/j.critrevonc.2022.103644 10.1186/s13063-016-1322-4 10.1586/egh.11.86 10.1186/1472-6963-6-161 10.1016/s0002-9149(02)03378-7 10.1016/j.jacc.2015.12.063 10.1161/CIRCULATIONAHA.115.018351 10.3389/fcvm.2015.00026 10.1016/j.tcm.2017.07.010 10.1111/j.1542-474x.1997.tb00325.x 10.1161/jaha.115.001820 |
ContentType | Journal Article |
Copyright | Neal Yuan, Adam Oesterle, Patrick Botting, Sumeet Chugh, Christine Albert, Joseph Ebinger, David Ouyang. Originally published in JMIR Cardio (https://cardio.jmir.org), 20.01.2023. 2023. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Neal Yuan, Adam Oesterle, Patrick Botting, Sumeet Chugh, Christine Albert, Joseph Ebinger, David Ouyang. Originally published in JMIR Cardio (https://cardio.jmir.org), 20.01.2023. 2023 |
Copyright_xml | – notice: Neal Yuan, Adam Oesterle, Patrick Botting, Sumeet Chugh, Christine Albert, Joseph Ebinger, David Ouyang. Originally published in JMIR Cardio (https://cardio.jmir.org), 20.01.2023. – notice: 2023. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Neal Yuan, Adam Oesterle, Patrick Botting, Sumeet Chugh, Christine Albert, Joseph Ebinger, David Ouyang. Originally published in JMIR Cardio (https://cardio.jmir.org), 20.01.2023. 2023 |
DBID | NPM AAYXX CITATION 3V. 7RV 7X7 7XB 8C1 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. KB0 M0S NAPCQ PIMPY PQEST PQQKQ PQUKI 7X8 5PM DOA |
DOI | 10.2196/41055 |
DatabaseName | PubMed CrossRef ProQuest Central (Corporate) ProQuest Nursing and Allied Health Journals Health & Medical Collection ProQuest Central (purchase pre-March 2016) Public Health Database (Proquest) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) Nursing & Allied Health Premium Publicly Available Content (ProQuest) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | PubMed CrossRef Publicly Available Content Database ProQuest Public Health ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Central Nursing & Allied Health Premium ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 2561-1011 |
ExternalDocumentID | oai_doaj_org_article_6fee1905c8324edf8cc1091981082b67 10_2196_41055 36662566 |
Genre | Journal Article |
GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: K23 HL153888 – fundername: NHLBI NIH HHS grantid: K99 HL157421 |
GroupedDBID | 7RV 7X7 8C1 8FI 8FJ AAFWJ ABUWG AFKRA AFPKN ALIPV ALMA_UNASSIGNED_HOLDINGS BENPR CCPQU FYUFA GROUPED_DOAJ HMCUK HYE M~E NAPCQ NPM OK1 PGMZT PIMPY RPM UKHRP AAYXX CITATION 3V. 7XB 8FK AZQEC DWQXO K9. PQEST PQQKQ PQUKI 7X8 5PM |
ID | FETCH-LOGICAL-c3725-6bea5c2298ae89590a0cbbf3b85b1c84031fe953799c4406589d0e82b2f806453 |
IEDL.DBID | RPM |
ISSN | 2561-1011 |
IngestDate | Tue Oct 22 15:00:53 EDT 2024 Tue Sep 17 21:30:34 EDT 2024 Sat Oct 26 03:54:33 EDT 2024 Fri Nov 29 08:17:40 EST 2024 Thu Nov 21 21:04:58 EST 2024 Sat Nov 02 12:22:14 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | clinical data monitoring accessibility comorbidity interaction ECG electronic health records monitoring pharmacovigilance EHR medication monitoring clinical data demographic interaction assessment electrocardiogram QT prolongation drug toxicity medication effects |
Language | English |
License | Neal Yuan, Adam Oesterle, Patrick Botting, Sumeet Chugh, Christine Albert, Joseph Ebinger, David Ouyang. Originally published in JMIR Cardio (https://cardio.jmir.org), 20.01.2023. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Cardio, is properly cited. The complete bibliographic information, a link to the original publication on https://cardio.jmir.org, as well as this copyright and license information must be included. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3725-6bea5c2298ae89590a0cbbf3b85b1c84031fe953799c4406589d0e82b2f806453 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-2081-1121 0000-0001-5782-7437 0000-0003-1847-8662 0000-0002-0587-1572 0000-0002-4417-5326 0000-0002-3813-7518 0000-0003-0967-5728 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898836/ |
PMID | 36662566 |
PQID | 2917611497 |
PQPubID | 4997109 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_6fee1905c8324edf8cc1091981082b67 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9898836 proquest_miscellaneous_2768235259 proquest_journals_2917611497 crossref_primary_10_2196_41055 pubmed_primary_36662566 |
PublicationCentury | 2000 |
PublicationDate | 20230120 |
PublicationDateYYYYMMDD | 2023-01-20 |
PublicationDate_xml | – month: 1 year: 2023 text: 20230120 day: 20 |
PublicationDecade | 2020 |
PublicationPlace | Canada |
PublicationPlace_xml | – name: Canada – name: Toronto – name: Toronto, Canada |
PublicationTitle | JMIR cardio |
PublicationTitleAlternate | JMIR Cardio |
PublicationYear | 2023 |
Publisher | JMIR Publications |
Publisher_xml | – name: JMIR Publications |
References | ref13 ref12 ref15 ref14 ref11 ref10 ref2 ref1 ref17 ref16 ref19 ref18 ref24 ref23 ref26 ref25 ref20 ref22 ref21 ref27 ref8 ref7 ref9 ref4 ref3 ref6 ref5 |
References_xml | – ident: ref8 doi: 10.1161/CIRCOUTCOMES.113.000152 – ident: ref12 doi: 10.1001/jama.2015.10725 – ident: ref14 doi: 10.5152/AnatolJCardiol.2015.6284 – ident: ref15 doi: 10.3265/Nefrologia.pre2012.Oct.11679 – ident: ref7 doi: 10.1016/j.mayocp.2013.01.013 – ident: ref21 doi: 10.1161/CIRCEP.118.007280 – ident: ref22 doi: 10.11909/j.issn.1671-5411.2016.09.013 – ident: ref25 doi: 10.1001/jamaoncol.2019.1870 – ident: ref9 doi: 10.1016/j.jacep.2016.12.005 – ident: ref2 doi: 10.1016/j.jacc.2010.01.001 – ident: ref10 doi: 10.1161/jaha.116.003264 – ident: ref23 doi: 10.1001/jama.270.21.2590 – ident: ref27 doi: 10.1016/j.rmed.2016.12.003 – ident: ref3 doi: 10.1016/j.hrthm.2015.07.011 – ident: ref1 doi: 10.1016/S0140-6736(99)02107-8 – ident: ref16 doi: 10.1111/bcpt.12081 – ident: ref18 doi: 10.1016/j.critrevonc.2022.103644 – ident: ref26 doi: 10.1186/s13063-016-1322-4 – ident: ref19 doi: 10.1586/egh.11.86 – ident: ref13 doi: 10.1186/1472-6963-6-161 – ident: ref24 doi: 10.1016/s0002-9149(02)03378-7 – ident: ref4 doi: 10.1016/j.jacc.2015.12.063 – ident: ref17 doi: 10.1161/CIRCULATIONAHA.115.018351 – ident: ref6 doi: 10.3389/fcvm.2015.00026 – ident: ref5 doi: 10.1016/j.tcm.2017.07.010 – ident: ref11 doi: 10.1111/j.1542-474x.1997.tb00325.x – ident: ref20 doi: 10.1161/jaha.115.001820 |
SSID | ssj0002511545 |
Score | 2.259506 |
Snippet | Drug-induced prolongation of the corrected QT interval (QTc) increases the risk for Torsades de Pointes (TdP) and sudden cardiac death. Medication effects on... Background:Drug-induced prolongation of the corrected QT interval (QTc) increases the risk for Torsades de Pointes (TdP) and sudden cardiac death. Medication... BackgroundDrug-induced prolongation of the corrected QT interval (QTc) increases the risk for Torsades de Pointes (TdP) and sudden cardiac death. Medication... |
SourceID | doaj pubmedcentral proquest crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | e41055 |
SubjectTerms | Cardiovascular disease Chronic obstructive pulmonary disease Comorbidity Coronary vessels Demographics Diabetes Drug stores Electrocardiography Electronic health records Heart failure Heart rate Hypertension Hypothesis testing Kidney diseases Liver diseases Long QT syndrome Original Paper Patients Pharmacy Vein & artery diseases |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA7iQQQRxVd9LBG8hm2TNE28qSjiwRe7sLfSpIkK0hXdPfjvnWnWsiuCFy-ldHpIZyaZb5LpN4SchMJJRN6sslIyWbmMQRBUrFC1Tl3mg45sn7fqeihvRvlortUX1oRFeuCouL4K3kPQyh24nvR10M4hl6XRGQQvq-J_5CmfS6ZwDUbgDNhghaxhrTN4WR_LGfOF4NNy9P8GLH_WR84FnKsNsj5DivQsjnCTLPlmi7xiXQYbxOY6b9MJPeuYNek40EeAfaytj6HxBAbVTiND8QeF24cBbfcAwb_o_TssfM1T-84pvbPd_izIsLzwc5sMry4HF9ds1jCBOVHwnCnrq9xxbnTltclNWqXO2iCszm3mIJUTWfAmF4UxTkoEH6ZOPaiRB428dWKHLDfjxu8RGnywoa6FMLWXteeV01WduhQuPoMFNCG9b02Wb5EXo4R8AlVdtqpOyDnqtxMijXX7AIxbzoxb_mXchBx-W6ecza2PkkOGqSCNMyA-7sQwK_Coo2r8eArvQBbFkenVJGQ3GrMbiYCMDYCeSkixYOaFoS5Kmpfnlnkbm21qofb_49sOyCq2rsftHJ4ekuXJ-9QfAcCZ2F7ry18h3Prt priority: 102 providerName: Directory of Open Access Journals – databaseName: Public Health Database (Proquest) dbid: 8C1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bi9UwEB50BRFEFG9d1yWCr2HbJE2TfZF1cVl88MZZ2LfS3FZB2uO5PPjvnUl7qkfEl1KaPISZZOabyfQbgNep8YqQN--cUlx1vuLoBDVvdDClr2IyI9vnB315pd5f19dTwm09lVXubGI21GHwlCM_ERhXaATvtnmz_MGpaxTdrk4tNG7DnYocHf0pfl7NORaCz4gQ7sJ9qnjGvXZCRY31ngvKTP3_gpd_V0n-4XYuHsKDCS-ys1HBj-BW7B_Dd6rO4Iuxxc5yu2FnM78mGxL7guCP5yoZNt7DkPDZyFO8Zvj6ecFyJhB3Gfu0QvPX3-Q5p-yjm7O0OEZFhj-fwNXFu8X5JZ_aJnAvG1Fz7WJXeyGs6aKxtS270juXpDO1qzwGdLJK0daysdYrRRDEhjIa4UQyxF4nn8JBP_TxObAUk0shSGlDVCGKzpsulL7ER0R1iAKOd5JslyM7RotRBYm6zaIu4C3Jdx4kMuv8YVjdtNPZaHWKEXFJ7dG6qBiS8Z7oSq2pEJ843RRwtNNOO52wdft7PxTwah7Gs0EXHl0fhy3OwVhKEN-rLeDZqMx5JRLjNoR7uoBmT817S90f6b99zfzb1HLTSH34_2W9gHvUmp7SNaI8goPNahtfIoDZuOO8S38Br_Hy0w priority: 102 providerName: ProQuest |
Title | High-Throughput Assessment of Real-World Medication Effects on QT Interval Prolongation: Observational Study |
URI | https://www.ncbi.nlm.nih.gov/pubmed/36662566 https://www.proquest.com/docview/2917611497 https://www.proquest.com/docview/2768235259 https://pubmed.ncbi.nlm.nih.gov/PMC9898836 https://doaj.org/article/6fee1905c8324edf8cc1091981082b67 |
Volume | 7 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB6SFEqhlJa-nKZGhV6VtSU_pN6SJSEUmm7DBvZmLFlKA4l32ewe-u8zIz_Ilp56McZjgxiNNd_In78B-OpLmxHy5rXJMp7VNuWYBAteFo1KbOq86tQ-L4uL6-z7Il_sQT78CxNI-9bcHrd398ft7e_ArVzd28nAE5vMfkyp56GSxWQf9jH9PinRafklzIyw4Dm8JJozBtiEmIzUoUYiVMcMX-ykoKDU_y94-TdL8knaOX8Nr3q8yE66cb2BPde-hTtiZ_B512Jntd2wk1Ffky09u0LwxwNLhnXfYcj5rNMpfmB4-mvOwk4gRhmbrXH5a2_CPd_YTzPu0qKNSIZ_3sH1-dl8esH7tgncylLkvDCuzq0QWtVO6VwndWKN8dKo3KQWCzqZeqdzWWpts4wgiG4Sp4QRXpF6nXwPB-2ydR-BeeeNbxopdeOyxonaqrpJbIIHl-IyGkE8eLJadeoYFVYV5PUqeD2CU_LvaCQx63Bhub6p-imtCu8c4pLc4uqSucYra0muVKsU8YkpygiOhtmp-jfsoRJYZxZYzGk0fxnN-G7QB4-6dcst3oO1lCC9Vx3Bh24yx5EMwRBBuTPNO0PdtWA4Bv3tPvwO__vJT_CCutbTTo5IjuBgs966z4htNibGiF6UeFTTNIZnp2eXs6s47BPEIcofAW1jAH8 |
link.rule.ids | 230,314,727,780,784,864,885,2102,12056,12223,21388,27924,27925,31719,31720,33266,33267,33744,33745,43310,43579,43805,53791,53793,73745,74014,74302 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bi9UwEB50BRVEFG_VdY3ga9g2adPEF1kXl6Ou64WzsG-lua2CtMdzefDfO5P2VI-IL6V0-hBmJpNvJsM3AC9i7UpC3ry1ZcnL1hUcD0HFa-V17ooQ9cD2eaZm5-W7i-piLLitxrbKbUxMgdr3jmrkhwLzCoXg3dSvFj84TY2i29VxhMZVuIbHfk1erY-LqcZC8BkRwnW4RR3P6GuH1NRY7RxBian_X_Dy7y7JP46dkztwe8SL7Ggw8F24Erp78J26M_h8GLGz2KzZ0cSvyfrIviD446lLhg33MKR8NvAUrxi-fp6zVAlEL2Oflhj-usv0z0v20U5VWpRRk-HP-3B-8mZ-POPj2ATuZC0qrmxoKyeE0W3QpjJ5mztro7S6soXDhE4WMZhK1sa4siQIYnwetLAiamKvkw9gr-u78AhYDNFG76U0PpQ-iNbp1ucux0dAc4gMDraabBYDO0aDWQWpukmqzuA16XcSEpl1-tAvL5txbzQqhoC4pHIYXcrgo3aO6EqNLhCfWFVnsL-1TjPusFXz2x8yeD6JcW_QhUfbhX6D_2AuJYjv1WTwcDDmtBKJeRvCPZVBvWPmnaXuSrpvXxP_No3c1FI9_v-ynsGN2fzDaXP69uz9E7hJY-qpdCPyfdhbLzfhKYKZtT1IHvsLZv_1zw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5BkSqkCoF4hZZiJK7WJnbi2L2g0rIqD5WCtlJvUezYBQkl230c-PfMONnAVohLFGVysDxj-5vxp28A3oTS5YS8eW3znOe1yzgegoqXqtGpy3zQvdrnuTq7zD9eFVcD_2k50Co3e2LcqJvOUY18IjCvUAjeTTkJAy3i4nT6dn7DqYMU3bQO7TTuwj3qMkc6-vokG-stBKURLezCHrGfMe4mRHAsto6jqNr_L6h5mzH51xE0fQgPBuzIjntnP4I7vn0MP4mpwWd9u535esWOR61N1gX2DYEgj4wZ1t_JkCNYr1m8ZPj6dcZiVRAjjl0scCtsr-M_R-yLHSu2aCPC4a8ncDl9Pzs540MLBe5kKQqurK8LJ4TRtdemMGmdOmuDtLqwmcPkTmbBm0KWxrg8JzhimtRrYUXQpGQnn8JO27X-ObDggw1NI6VpfN54UTtdN6lL8eHRNSKBw81MVvNeKaPCDIOmuopTncA7mt_RSMLW8UO3uK6GdVKp4D1ilMLhTpP7JmjnSLrU6AyxilVlAgcb71TDaltWf2IjgdejGdcJXX7Ure_W-A_mVYK0X00Cz3pnjiORmMMh9FMJlFtu3hrqtqX98T1qcVP7TS3Vi_8P6xXsYrBWnz-cf9qH-9Sxnqo4Ij2AndVi7V8irlnZwxiwvwGGD_n0 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=High-Throughput+Assessment+of+Real-World+Medication+Effects+on+QT+Interval+Prolongation%3A+Observational+Study&rft.jtitle=JMIR+cardio&rft.au=Yuan%2C+Neal&rft.au=Oesterle%2C+Adam&rft.au=Botting%2C+Patrick&rft.au=Chugh%2C+Sumeet&rft.date=2023-01-20&rft.pub=JMIR+Publications&rft.eissn=2561-1011&rft.volume=7&rft.spage=e41055&rft_id=info:doi/10.2196%2F41055&rft.externalDBID=HAS_PDF_LINK |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2561-1011&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2561-1011&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2561-1011&client=summon |